Sign up
PRME

Prime Medicine, Inc. Common Stock (NASDAQ: PRME)

Healthcare · Biotechnology

——

Quote unavailable · Price data is temporarily unavailable.

Set alert

The Quantellect read. The borrow fee is 0.36%. Five active firms cover the stock as of Nov 19, 2026; four active firms with targets average $8.75 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuationMixed valuation signals

P/S 210.2× vs peer median 13.9×

MomentumNeutral

RSI (14) 47.5 (overbought above 70, oversold below 30)

Trend—

—

Short interest26.0% of float

FINRA settlement Oct 30, 2026

PRME price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range—
Volume—
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

PRME · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

— · Quantellect signals not available

How PRME compares with its industry

Against 592 other US-listed Biotechnology stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. Three-month return was 17.9%, higher than 92% of 558 peers.Peer median −29.9% · As of Nov 17, 2026

Points of caution

  1. Trailing-year return on equity was -373.3%, with only 10% of 554 peers reporting a lower value.Peer median −67.8% · As of Nov 17, 2026
  2. Trailing-year net margin was 0%, with only 19% of 583 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026
  3. Current ratio was 1.79, with only 21% of 498 peers reporting a lower value.Peer median 5.03 · As of Nov 17, 2026

Valuation

Mixed valuation signals

  • Price/sales210.19×13.85×

    Higher than 85% of 407 peers

  • Forward P/E—14.90×

    Not ranked: only 194 of 592 peers report it

  • Price/book0.43×2.58×
    Lowest 10%

    Higher than 10% of 551 peers

Profitability

Profitability metrics are lower than most peers.

  • Gross margin—78.4%

    Not ranked: only 247 of 592 peers report it

  • Operating margin—0.0%

    Not ranked: only 443 of 592 peers report it

  • Net margin0.0%0.0%

    Higher than 19% of 583 peers

  • Return on equity−373.3%−67.8%
    Bottom 10% of peers

    Higher than 10% of 554 peers

Growth

Growth metrics are higher than most peers.

  • Quarterly sales growth, year over year3.5%0.0%

    Higher than 71% of 592 peers

  • 5-year sales growth rate−2.3%11.6%

    Not ranked: only 139 of 592 peers report it

Balance sheet

Balance sheet metrics are lower than most peers.

  • Current ratio1.795.03

    Higher than 21% of 498 peers

  • Debt/equity (total borrowings)—0.23

    Not ranked: only 117 of 592 peers report it

Momentum

Returns are higher than most peers.

  • 1-year return0.0%−28.4%

    Higher than 67% of 522 peers

  • 6-month return+35.0%−26.7%

    Higher than 86% of 545 peers

  • 3-month return+17.9%−29.9%
    Top 10% of peers

    Higher than 92% of 558 peers

Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 13, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

0Strong Buy
5Buy
0Neutral
0Sell
0Strong Sell

Based on 5 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$7.00
Average$8.75
High$11.00

As of Nov 19, 2026 across 4 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

— · Earnings history not available

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider buyGV 2021 GP, L.L.C. / GV 2021 GP, L.P. / GV 2021, L.P. / Alphabet Inc.Buy$5.0MForm 4
Insider buyNELSEN ROBERTBuy$10.0MForm 4
Insider buyARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P.Buy$10.0MForm 4
Insider buyARCH Venture Partners X, LLC / ARCH Venture Partners X, L.P. / ARCH Venture Partners X Overage, L.P. / ARCH Venture Fund X, L.P. / ARCH Venture Fund X Overage, L.P. / CRANDELL KEITH / Burow Kristina / GILLIS STEVENBuy$10.0MForm 4
Insider buyLiu David R.Buy$52.8KForm 4
Insider buyLiu David R.Buy$45.4KForm 4
Insider buyLiu David R.Buy$31.2KForm 4
Insider buyLiu David R.Buy$33.6KForm 4
Insider buyBrudnick RichardBuy$23.8KForm 4
Insider buyLEE ANN L.Buy$113.0KForm 4
All smart-money activity →

News and press releases

All PRME news →

Company profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that

CEO
Dr. Allan Reine M.D.
Headquarters
Cambridge, MA, United States
Employees
146
IPO date
Oct 20, 2022
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.